Geneuro Provides Access to Presentations from HERVs and Disease
Workshop Held in Washington, DC

GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 – GNRO), a
biopharmaceutical company developing new treatments for neurological
disorders and autoimmune diseases, including multiple sclerosis (MS),
today provided access to research on human endogenous retroviruses
(HERVs) and their impact on neurological pathologies. At the recent 2nd
International Workshop on Human Endogenous Retroviruses and Disease,
held in Washington, DC, experts from around the world gathered to
discuss topics focusing on nervous system diseases, such as HERV-W
envelope protein (MSRV-Env) and its role in multiple sclerosis (MS), how
activated HERV-K and its envelope protein cause pathogenic effects
relevant for amyotrophic lateral sclerosis and the potential link of
HERVs to psychoses. Past, ongoing and future therapeutic strategies in
clinical trials targeting HERVs in these diseases were also presented
and discussed between the clinicians and scientific experts.

Hervé Perron, Chief Scientific Officer of GeNeuro, said: “The HERV and
Disease meeting provides a unique opportunity for scientific and
clinical experts to share their knowledge and experience in the field.
Momentum in HERV medical research as well as therapeutic development is
now building rapidly.”

GeNeuro is conducting a Phase 2b clinical study with GNbAC1, a
monoclonal antibody designed to neutralize MSRV-Env, a pathogenic
protein that has been associated with both the inflammatory and
neurodegenerative components of the disease. GeNeuro expects top-line
results from this study, made in partnership with Servier, to be
available early in the fourth quarter 2017.

GeNeuro‘s mission is to develop safe and effective treatments against
neurological disorders and autoimmune diseases, such as multiple
sclerosis, by neutralizing causal factors encoded by HERVs, which
represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in France
at sites in Archamps, Haute-Savoie and in Lyon. It has 30 employees and
rights to 16 patent families protecting its technology.

This press release contains certain forward - looking statements and
estimates concerning GeNeuro’s financial condition, operating results,
strategy, projects and future performance and the markets in which it
operates. Such forward-looking statements and estimates may be
identified by words, such as “anticipate,” “believe,” “can,” “could,”
“estimate,” “expect,” “intend,” “is designed to,” “may,” “might,”
“plan,” “potential,” “predict,” “objective,” “should,” or the negative
of these and similar expressions. They incorporate all topics that are
not historical facts. Forward looking statements, forecasts and
estimates are based on management’s current assumptions and assessment
of risks, uncertainties and other factors, known and unknown, which were
deemed to be reasonable at the time they were made but which may turn
out to be incorrect. Events and outcomes are difficult to predict and
depend on factors beyond the company’s control. Consequently, the actual
results, financial condition, performances and/or achievements of
GeNeuro or of the industry may turn out to differ materially from the
future results, performances or achievements expressed or implied by
these statements, forecasts and estimates. Owing to these uncertainties,
no representation is made as to the correctness or fairness of these
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates speak only as of the
date on which they are made, and GeNeuro undertakes no obligation to
update or revise any of them, whether as a result of new information,
future events or otherwise, except as required by law.